U.S. venture capital firms are increasingly embedding themselves in Chinese labs and courting scientists before their research is published, moving upstream in biotech investments due to fierce competition and rising valuations. This shift impacts tech professionals by accelerating the commercialization of scientific discoveries and altering traditional investment timelines. Watch for more collaborations between U.S. VCs and local partners as they seek early-stage innovations.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
15
Ali NematiWritten by Ali
